Mariner’s ProQR Therapeutics PRQR Stock Holding History

Mariner’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.7K	Buy	20,169 +950	+5%	+$1.56K	﹤0.01%	3462
2025 Q4	$38.8K	Hold	19,219	–	–	﹤0.01%	3439
2025 Q3	$40.9K	Hold	19,219	–	–	﹤0.01%	3469
2025 Q2	$39.2K	Buy	19,219 +885	+5%	+$1.44K	﹤0.01%	3370
2025 Q1	$24.4K	Hold	18,334	–	–	﹤0.01%	3363
2024 Q4	$48.6K	Hold	18,334	–	–	﹤0.01%	3291
2024 Q3	$33.5K	Hold	18,334	–	–	﹤0.01%	3222
2024 Q2	$30.4K	Hold	18,334	–	–	﹤0.01%	3087
2024 Q1	$42K	Hold	18,334	–	–	﹤0.01%	3046
2023 Q4	$36.3K	Hold	18,334	–	–	﹤0.01%	2965
2023 Q3	$23.8K	Hold	18,334	–	–	﹤0.01%	2834
2023 Q2	$29.7K	Hold	18,334	–	–	﹤0.01%	2760
2023 Q1	$39K	Hold	18,334	–	–	﹤0.01%	2671
2022 Q4	$68K	Buy	+18,334	New	+$24K	﹤0.01%	2582

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Mariner's PRQR Position: Q1 2026 in Review

Mariner increased its ProQR Therapeutics (PRQR) stake by 4.9% in Q1 2026, buying an estimated $1.56K and bringing the position to 20,169 shares worth $32.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3462.

Mariner first reported a position in PRQR in Q4 2022 and has held it in 14 quarters since. The position peaked at $68K in Q4 2022. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Mariner held 20,169 shares of ProQR Therapeutics worth $32.7K as of Q1 2026.
Mariner bought 950 ProQR Therapeutics shares in Q1 2026, an estimated $1.56K.
ProQR Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #3462 holding.
Mariner first reported a position in ProQR Therapeutics in Q4 2022 and has held it in 14 quarters since.
Mariner's ProQR Therapeutics position peaked at $68K in Q4 2022.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.